John Mendelson, MD
MendelJE@cpmcri.org
John Mendelson is a board certified Internist who has performed human pharmacologic studies with methamphetamine, MDMA, cocaine and buprenorphine. His clinical research involves the pharmacology, physiology and psych-ology of commonly abused drugs and development of treatments for drug abuse and associated medical and psychiatric complications. In his laboratory, pharmacologically active doses of abusable drugs are studied under controlled conditions. All studies are performed at or above FDA GLP standards and his clinical research unit is equipped to ethically and safely conduct studies in licit and illicit drug users.
He has successfully conducted NIH funded studies with methamphetamine, MDMA, cocaine, methamphetamine enantiomers, marijuana, opioids, and other addictive drugs in populations that are often difficult to deal with (including untreated cocaine and heroin addicts). He has studied the cardiovascular effects of MDMA, cocaine and methamphetamine. He has performed studies on interactions between ethanol and the stimulant drugs cocaine and methamphetamine and has developed novel cocaine self-administration paradigms. He has used stable isotope methods to define the pharmacokinetics of cocaethylene formation and elimination and measure the bioavailability of intranasal methamphetamine. Dr. Mendelson performed many of the basic pharmacokinetic and abuse liability studies used to support FDA approval of Suboxone (a combination of buprenorphine and naloxone), the first new primary pharmacotherapy for opiate addiction introduced in more than 30 years. Currently, he is conducting phase 1 safety interaction studies with potential new pharmacotherapies for methamphetamine addiction. Dr. Mendelson has extensive experience working with the many regulatory bodies that oversee research with addictive drugs, including the CPMC and UCSF Institutional Review Boards, the FDA, the UCSF General Clinical Research Center, and the California Research Advisory Panel.
Click here for List of publications by J Mendelson, M.D. in PubMed.
Back to top
Gantt Galloway, Pharm.D.
Gantt@cpmcri.org
Dr. Gantt Galloway brings 16 years of research and clinical experience with alcoholics and other addicts to the group. He has worked in a number of treatment settings, such as the Haight-Ashbury Free Clinic. Together with Dr. Mendelson, he founded the Addiction Pharmacology Research Laboratory at California Pacific Medical Center. He has succeeded in designing and conducting clinical research with NIH funding in challenging clinical settings. Naltrexone and nalmefene are among the agents that he has tested for alcohol dependence. He has tested naltrexone as a treatment for methamphetamine dependence and for cocaine dependence. His research interests also include genetic contributions to the development of paranoia in methamphetamine users.
Click here for list of publications by Gantt Galloway, Pharm.D. in PubMed.
Back to top
Matthew Baggott, PhD
matthew@baggott.net
Click here for List of publications by M Baggott in PubMed.
Back to top